JP6502939B2 - 骨粗鬆症の処置及び予防のためのガストリン拮抗薬 - Google Patents
骨粗鬆症の処置及び予防のためのガストリン拮抗薬 Download PDFInfo
- Publication number
- JP6502939B2 JP6502939B2 JP2016533607A JP2016533607A JP6502939B2 JP 6502939 B2 JP6502939 B2 JP 6502939B2 JP 2016533607 A JP2016533607 A JP 2016533607A JP 2016533607 A JP2016533607 A JP 2016533607A JP 6502939 B2 JP6502939 B2 JP 6502939B2
- Authority
- JP
- Japan
- Prior art keywords
- gastrin
- bone
- hypergastrinemia
- cells
- ovariectomy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 title claims description 360
- 108010052343 Gastrins Proteins 0.000 title claims description 347
- 238000011282 treatment Methods 0.000 title claims description 70
- 208000001132 Osteoporosis Diseases 0.000 title claims description 53
- 239000005557 antagonist Substances 0.000 title claims description 35
- 102100021022 Gastrin Human genes 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title description 12
- 210000000988 bone and bone Anatomy 0.000 claims description 257
- 206010060377 Hypergastrinaemia Diseases 0.000 claims description 156
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 119
- 229960001340 histamine Drugs 0.000 claims description 59
- 208000020084 Bone disease Diseases 0.000 claims description 34
- YDZYKNJZCVIKPP-VWLOTQADSA-N netazepide Chemical compound CNC1=CC=CC(NC(=O)N[C@H]2C(N(CC(=O)C(C)(C)C)C3=CC=CC=C3C(C=3N=CC=CC=3)=N2)=O)=C1 YDZYKNJZCVIKPP-VWLOTQADSA-N 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 9
- 239000000612 proton pump inhibitor Substances 0.000 claims description 9
- 201000004535 ovarian dysfunction Diseases 0.000 claims description 6
- 206010033165 Ovarian failure Diseases 0.000 claims description 5
- 230000001613 neoplastic effect Effects 0.000 claims description 5
- 231100000539 ovarian failure Toxicity 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 2
- 231100000542 impaired ovarian function Toxicity 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 102400000921 Gastrin Human genes 0.000 description 356
- 241001465754 Metazoa Species 0.000 description 181
- 230000000849 parathyroid Effects 0.000 description 162
- 230000000694 effects Effects 0.000 description 150
- 238000009806 oophorectomy Methods 0.000 description 149
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 85
- 210000004027 cell Anatomy 0.000 description 82
- 230000002829 reductive effect Effects 0.000 description 80
- 229940011871 estrogen Drugs 0.000 description 74
- 239000000262 estrogen Substances 0.000 description 74
- 230000014509 gene expression Effects 0.000 description 74
- 239000003743 cholecystokinin B receptor antagonist Substances 0.000 description 73
- 230000007774 longterm Effects 0.000 description 72
- 230000001404 mediated effect Effects 0.000 description 67
- 210000000712 G cell Anatomy 0.000 description 65
- 239000011575 calcium Substances 0.000 description 64
- 241001416505 Mastomys Species 0.000 description 61
- 230000001054 cortical effect Effects 0.000 description 61
- 230000028327 secretion Effects 0.000 description 52
- 108010014095 Histidine decarboxylase Proteins 0.000 description 49
- 102100037095 Histidine decarboxylase Human genes 0.000 description 49
- 239000003795 chemical substances by application Substances 0.000 description 45
- 230000002496 gastric effect Effects 0.000 description 45
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 41
- 210000000963 osteoblast Anatomy 0.000 description 41
- 230000004913 activation Effects 0.000 description 40
- 102000005962 receptors Human genes 0.000 description 40
- 108020003175 receptors Proteins 0.000 description 40
- 230000008685 targeting Effects 0.000 description 40
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 38
- 229910052791 calcium Inorganic materials 0.000 description 38
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 37
- 210000001185 bone marrow Anatomy 0.000 description 34
- 230000001965 increasing effect Effects 0.000 description 34
- 102000052874 Gastrin receptors Human genes 0.000 description 33
- 210000002997 osteoclast Anatomy 0.000 description 32
- 238000010603 microCT Methods 0.000 description 31
- 230000037118 bone strength Effects 0.000 description 30
- 210000002784 stomach Anatomy 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000005259 measurement Methods 0.000 description 27
- 238000000034 method Methods 0.000 description 27
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 26
- 230000006870 function Effects 0.000 description 25
- 108060001064 Calcitonin Proteins 0.000 description 24
- 206010017076 Fracture Diseases 0.000 description 24
- 102000055006 Calcitonin Human genes 0.000 description 23
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 23
- 229960004015 calcitonin Drugs 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 23
- 210000001685 thyroid gland Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 206010065687 Bone loss Diseases 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 21
- 230000037182 bone density Effects 0.000 description 21
- 210000004188 enterochromaffin-like cell Anatomy 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 230000003247 decreasing effect Effects 0.000 description 20
- 108091005932 CCKBR Proteins 0.000 description 19
- 230000010072 bone remodeling Effects 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 229940088597 hormone Drugs 0.000 description 19
- 239000005556 hormone Substances 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- ARLKVQYMFRECLV-JSGCOSHPSA-N (2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(N)=O)=CNC2=C1 ARLKVQYMFRECLV-JSGCOSHPSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 18
- 210000000689 upper leg Anatomy 0.000 description 18
- 230000003915 cell function Effects 0.000 description 17
- 230000007423 decrease Effects 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 208000010392 Bone Fractures Diseases 0.000 description 15
- 210000003771 C cell Anatomy 0.000 description 15
- 230000018678 bone mineralization Effects 0.000 description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 14
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 208000006735 Periostitis Diseases 0.000 description 13
- 230000024279 bone resorption Effects 0.000 description 13
- 230000011164 ossification Effects 0.000 description 13
- 230000002611 ovarian Effects 0.000 description 13
- 210000003460 periosteum Anatomy 0.000 description 13
- 238000011533 pre-incubation Methods 0.000 description 13
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 12
- 229960005309 estradiol Drugs 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 208000006386 Bone Resorption Diseases 0.000 description 11
- 108010025832 RANK Ligand Proteins 0.000 description 11
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 229940076279 serotonin Drugs 0.000 description 11
- 230000003491 cAMP production Effects 0.000 description 10
- 229930182833 estradiol Natural products 0.000 description 10
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 10
- 230000003248 secreting effect Effects 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 102100038595 Estrogen receptor Human genes 0.000 description 9
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 9
- -1 PTH1R Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000004412 neuroendocrine cell Anatomy 0.000 description 9
- 229940044551 receptor antagonist Drugs 0.000 description 9
- 239000002464 receptor antagonist Substances 0.000 description 9
- 239000000556 agonist Substances 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 230000004094 calcium homeostasis Effects 0.000 description 8
- 238000013110 gastrectomy Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000010606 normalization Methods 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 7
- 230000009858 acid secretion Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 230000001668 ameliorated effect Effects 0.000 description 7
- 210000002449 bone cell Anatomy 0.000 description 7
- 230000037186 bone physiology Effects 0.000 description 7
- 230000002308 calcification Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 210000002406 gastrin-secreting cell Anatomy 0.000 description 7
- 210000004349 growth plate Anatomy 0.000 description 7
- 230000000955 neuroendocrine Effects 0.000 description 7
- 229910052762 osmium Inorganic materials 0.000 description 7
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000007634 remodeling Methods 0.000 description 7
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 6
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 6
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 6
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000043136 MAP kinase family Human genes 0.000 description 6
- 108091054455 MAP kinase family Proteins 0.000 description 6
- 208000029725 Metabolic bone disease Diseases 0.000 description 6
- 108010016076 Octreotide Proteins 0.000 description 6
- 102000004067 Osteocalcin Human genes 0.000 description 6
- 108090000573 Osteocalcin Proteins 0.000 description 6
- 102000003982 Parathyroid hormone Human genes 0.000 description 6
- 108090000445 Parathyroid hormone Proteins 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 230000004097 bone metabolism Effects 0.000 description 6
- 210000001612 chondrocyte Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000002651 drug therapy Methods 0.000 description 6
- 108010038795 estrogen receptors Proteins 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 102000058004 human PTH Human genes 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 229960002700 octreotide Drugs 0.000 description 6
- 238000013001 point bending Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 230000001720 vestibular Effects 0.000 description 6
- 235000019166 vitamin D Nutrition 0.000 description 6
- 239000011710 vitamin D Substances 0.000 description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 description 6
- 229940046008 vitamin d Drugs 0.000 description 6
- 108010038447 Chromogranin A Proteins 0.000 description 5
- 102000010792 Chromogranin A Human genes 0.000 description 5
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 5
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 5
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 5
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 5
- 206010049088 Osteopenia Diseases 0.000 description 5
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 230000004821 effect on bone Effects 0.000 description 5
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- 210000001711 oxyntic cell Anatomy 0.000 description 5
- 210000002990 parathyroid gland Anatomy 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229950003937 tolonium Drugs 0.000 description 5
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 102100032187 Androgen receptor Human genes 0.000 description 4
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 4
- 108060000200 adenylate cyclase Proteins 0.000 description 4
- 102000030621 adenylate cyclase Human genes 0.000 description 4
- 108010080146 androgen receptors Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000033558 biomineral tissue development Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000005088 multinucleated cell Anatomy 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 230000004072 osteoblast differentiation Effects 0.000 description 4
- 230000001582 osteoblastic effect Effects 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 229940043437 protein kinase A inhibitor Drugs 0.000 description 4
- 239000012656 protein kinase A inhibitor Substances 0.000 description 4
- 108010065251 protein kinase modulator Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011808 rodent model Methods 0.000 description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 3
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 3
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 206010067994 Mucosal atrophy Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000011496 cAMP-mediated signaling Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- VTLNPNNUIJHJQB-UHFFFAOYSA-N loxtidine Chemical compound CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 VTLNPNNUIJHJQB-UHFFFAOYSA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 3
- 230000001515 vagal effect Effects 0.000 description 3
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 3
- RGGLEJFUEMKQSH-UHFFFAOYSA-N 1,4-benzodiazepin-2-one Chemical compound O=C1C=NC=C2C=CC=CC2=N1 RGGLEJFUEMKQSH-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 108010051479 Bombesin Proteins 0.000 description 2
- 102000013585 Bombesin Human genes 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 108010001789 Calcitonin Receptors Proteins 0.000 description 2
- 102100038520 Calcitonin receptor Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101710190440 Cytotoxin 1 Proteins 0.000 description 2
- 208000013558 Developmental Bone disease Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 2
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 2
- 102000000543 Histamine Receptors Human genes 0.000 description 2
- 108010002059 Histamine Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 101710191547 Peptidyl-tRNA hydrolase 1 Proteins 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 206010072610 Skeletal dysplasia Diseases 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940124325 anabolic agent Drugs 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 2
- 230000004221 bone function Effects 0.000 description 2
- 230000008412 bone pathophysiology Effects 0.000 description 2
- 230000009992 cAMP activation Effects 0.000 description 2
- 108060001061 calbindin Proteins 0.000 description 2
- 102000014823 calbindin Human genes 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002745 epiphysis Anatomy 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 201000002818 limb ischemia Diseases 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003349 osteoarthritic effect Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000009038 pharmacological inhibition Effects 0.000 description 2
- 230000007180 physiological regulation Effects 0.000 description 2
- 230000006461 physiological response Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 102220047090 rs6152 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 229960005460 teriparatide Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 2
- MFOOVZCXWVAWOV-RUZDIDTESA-N (3r)-5-[2-(8-azaspiro[4.5]decane-8-carbonyl)-4,6-dimethylanilino]-3-naphthalen-1-yl-5-oxopentanoic acid Chemical compound C=1C(C)=CC(C)=C(NC(=O)C[C@H](CC(O)=O)C=2C3=CC=CC=C3C=CC=2)C=1C(=O)N(CC1)CCC21CCCC2 MFOOVZCXWVAWOV-RUZDIDTESA-N 0.000 description 1
- FJCZHMXAGBYXHJ-QGZVFWFLSA-N (4r)-5-(8-azaspiro[4.5]decan-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-5-oxopentanoic acid Chemical compound N([C@H](CCC(=O)O)C(=O)N1CCC2(CCCC2)CC1)C(=O)C1=CC(Cl)=CC(Cl)=C1 FJCZHMXAGBYXHJ-QGZVFWFLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- KOLPMNSDISYEBU-WJOKGBTCSA-N 2-[(3r)-1-(2,2-diethoxyethyl)-3-[(4-methylphenyl)carbamoylamino]-2-oxoindol-3-yl]-n-(4-methylphenyl)acetamide Chemical compound C([C@]1(NC(=O)NC=2C=CC(C)=CC=2)C(=O)N(C2=CC=CC=C21)CC(OCC)OCC)C(=O)NC1=CC=C(C)C=C1 KOLPMNSDISYEBU-WJOKGBTCSA-N 0.000 description 1
- PUMGFEMNXBLDKD-UHFFFAOYSA-N 3,6-diaminoacridine-9-carbonitrile Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C(C#N)=C21 PUMGFEMNXBLDKD-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010072395 Atypical fracture Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001135732 Bos taurus Parathyroid hormone Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 101150027751 Casr gene Proteins 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 102100027368 Histone H1.3 Human genes 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 1
- 101001009450 Homo sapiens Histone H1.3 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000700167 Mastomys natalensis Species 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- IEKOTSCYBBDIJC-UHFFFAOYSA-N N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine Chemical compound CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 IEKOTSCYBBDIJC-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000033793 Neuroendocrine tumor of stomach Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000015197 Pancoast syndrome Diseases 0.000 description 1
- 201000010630 Pancoast tumor Diseases 0.000 description 1
- 101800005322 Pancreastatin Proteins 0.000 description 1
- 102400000203 Pancreastatin Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101150058700 Tph1 gene Proteins 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 1
- 108010075344 Tryptophan synthase Proteins 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000002280 acid secreting cell Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 230000000125 calcaemic effect Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 108010066264 gastrin 17 Proteins 0.000 description 1
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000000796 hypoacidity effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229950001743 itriglumide Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229950000165 lorglumide Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000004079 mineral homeostasis Effects 0.000 description 1
- 238000009343 monoculture Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017970 negative regulation of osteoblast differentiation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229950010986 netazepide Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- RYZUEKXRBSXBRH-CTXORKPYSA-N pancreastatin Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)C1=CN=CN1 RYZUEKXRBSXBRH-CTXORKPYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000026011 regulation of ossification Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229950011476 spiroglumide Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000036506 well differentiated low or intermediate grade gastric neuroendocrine tumor Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907980P | 2013-11-22 | 2013-11-22 | |
| US61/907,980 | 2013-11-22 | ||
| PCT/US2014/066832 WO2015077572A1 (en) | 2013-11-22 | 2014-11-21 | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538295A JP2016538295A (ja) | 2016-12-08 |
| JP2016538295A5 JP2016538295A5 (enExample) | 2017-12-28 |
| JP6502939B2 true JP6502939B2 (ja) | 2019-04-17 |
Family
ID=52118000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533607A Active JP6502939B2 (ja) | 2013-11-22 | 2014-11-21 | 骨粗鬆症の処置及び予防のためのガストリン拮抗薬 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10709714B2 (enExample) |
| EP (1) | EP3071206B1 (enExample) |
| JP (1) | JP6502939B2 (enExample) |
| KR (1) | KR102254957B1 (enExample) |
| CN (1) | CN106163527A (enExample) |
| AU (1) | AU2014352875B2 (enExample) |
| BR (1) | BR112016011727A2 (enExample) |
| CA (1) | CA2929858C (enExample) |
| DK (1) | DK3071206T3 (enExample) |
| ES (1) | ES2870538T3 (enExample) |
| MX (1) | MX2016006657A (enExample) |
| PL (1) | PL3071206T3 (enExample) |
| RU (1) | RU2693484C1 (enExample) |
| WO (1) | WO2015077572A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10881667B2 (en) | 2018-10-30 | 2021-01-05 | City University Of Hong Kong | Method and composition for treating epilepsy |
| US11285161B2 (en) | 2019-04-26 | 2022-03-29 | City University Of Hong Kong | Method and composition for treating mental disorder and pain associated with nerve damage |
| CN110935005A (zh) * | 2019-11-19 | 2020-03-31 | 宁波大学 | 一种丙谷二肽的新用途 |
| CN115770266B (zh) * | 2023-01-30 | 2023-05-09 | 云南中医药大学 | 一种用于治疗绝经后骨质疏松的药物组合物 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989005812A1 (fr) | 1987-12-22 | 1989-06-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de thienodiazepine et leur utilisation en medecine |
| DE69017302T3 (de) | 1989-08-04 | 1999-08-05 | Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. |
| US5399565A (en) | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
| HUT67299A (en) | 1990-12-25 | 1995-03-28 | Yamanouchi Pharma Co Ltd | Novel benzodiazepine derivetives, pharmaceutical compositions contaning them and process for their producing |
| CZ282536B6 (cs) | 1991-07-12 | 1997-08-13 | Warner-Lambert Company | Nepřirozený dipeptoid pro výrobu léčiva pro prevenci a léčbu záchvatů panického strachu |
| CA2120939A1 (en) | 1991-10-11 | 1993-04-15 | Tetsuya Tahara | Therapeutic agent for osteoporosis and diazepine compound |
| AU3247593A (en) * | 1991-12-20 | 1993-07-28 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| IL104853A (en) | 1992-02-27 | 1997-11-20 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them |
| JP3419539B2 (ja) | 1993-02-17 | 2003-06-23 | 中外製薬株式会社 | インドリン−２−オン誘導体 |
| GB2282595A (en) | 1993-08-25 | 1995-04-12 | Yamanouchi Pharma Co Ltd | Benzodiazepine derivatives |
| IT1261255B (it) | 1993-09-09 | 1996-05-09 | Rotta Research Lab | Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico. |
| EP0869975B1 (en) | 1995-12-11 | 2007-08-15 | New England Medical Center Hospitals, Inc. | Assay for and uses of peptide hormone receptor ligands |
| US5750353A (en) | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
| US5922883A (en) | 1996-04-03 | 1999-07-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US20040001842A1 (en) | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| ES2227833T3 (es) | 1997-05-12 | 2005-04-01 | Aphton Corporation | Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores. |
| EP1076561B1 (en) | 1998-05-15 | 2005-03-30 | Aphton Corporation | Combination therapy for the treatment of tumors |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| IL139811A0 (en) | 1998-06-04 | 2002-02-10 | Abbott Lab | Cell adhesion-inhibiting antinflammatory compounds |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| DE60016384T2 (de) | 1999-01-29 | 2005-12-01 | Chugai Seiyaku K.K. | Chondrogonese promotoren und indolin-2-on derivate |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| US20030191279A1 (en) | 1999-08-27 | 2003-10-09 | Goldstein Steven Wayne | Urea derivatives useful as anticancer agents |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| ES2259617T3 (es) | 1999-11-05 | 2006-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Compuestos heterociclicos y su aplicacion como medicamentos. |
| WO2001035899A2 (en) | 1999-11-19 | 2001-05-25 | Axxima Pharmaceuticals Ag | Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| AU2001253024A1 (en) | 2000-04-10 | 2001-10-23 | The General Hospital Corporation | Diagnosis and treatment of gastrointestinal disease |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| AU2002252456A1 (en) | 2001-03-23 | 2002-10-08 | Aphton Corporation | Combination treatment of pancreatic cancer |
| EP1391211A1 (en) | 2001-04-27 | 2004-02-25 | Chugai Seiyaku Kabushiki Kaisha | Chondrogenesis promoters |
| US20090191232A1 (en) | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| CA2445477A1 (en) | 2001-05-11 | 2002-11-21 | Yamanouchi Pharmaceutical Co., Ltd. | Antitumor agents |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| CN100348196C (zh) | 2001-11-13 | 2007-11-14 | 詹姆士布莱克基金会有限公司 | 作为胃泌激素和缩胆囊肽受体配体的苯并三氮杂䓬 |
| EP1478357B1 (en) | 2002-02-19 | 2007-01-31 | Pfizer Italia S.r.l. | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
| DE10207037A1 (de) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| UA79804C2 (en) | 2002-07-03 | 2007-07-25 | Janssen Pharmaceutica Nv | Cck-1 receptor modulators |
| US20030049698A1 (en) | 2002-10-08 | 2003-03-13 | Wang Timothy C. | Diagnosis and treatment of gastrointestinal disease |
| CA2520546A1 (en) | 2003-03-28 | 2005-02-10 | Janssen Pharmaceutica, N.V. | Benzo[1,2,5]thiadiazole compounds |
| GB0310865D0 (en) | 2003-05-12 | 2003-06-18 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| WO2004101533A1 (en) | 2003-05-12 | 2004-11-25 | Janssen Pharmaceutica, N.V. | 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands |
| WO2005007107A2 (en) * | 2003-07-11 | 2005-01-27 | University Of Massachusetts | Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer |
| CA2534887A1 (en) | 2003-08-08 | 2005-02-24 | Janssen Pharmaceutica, N.V. | Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds |
| US20070293482A1 (en) | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7947833B2 (en) | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| MX2007003623A (es) | 2004-09-24 | 2007-09-11 | Johnson & Johnson | Compuestos sulfonamida. |
| EP1817333A4 (en) | 2004-10-12 | 2008-12-31 | Janssen Pharmaceutica Nv | CHOLECYSTOKININ-1 RECEPTOR MATERIALS OF DOGS AND THEIR USE |
| WO2006049941A2 (en) | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
| WO2006052542A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as cb1 antagonists |
| GB0425196D0 (en) | 2004-11-15 | 2004-12-15 | Black James Foundation | Gastrin and cholecystokinin receptor ligands |
| WO2006064339A1 (en) | 2004-12-17 | 2006-06-22 | Pfizer Japan Inc. | Chromane derivatives useful as acid pump antagonists |
| US20080161293A1 (en) | 2005-01-19 | 2008-07-03 | Zeria Pharmaceutical Co., Ltd. | Antitumor Agent |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| JP5197361B2 (ja) | 2005-06-06 | 2013-05-15 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 睡眠障害を処置するための組成物および方法 |
| WO2006134460A1 (en) | 2005-06-14 | 2006-12-21 | Pfizer Japan Inc. | Chromane substituted benzimidazole derivatives as acid pump antagonists |
| DE602005013372D1 (de) | 2005-07-29 | 2009-04-30 | Rottapharm Spa | Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten |
| WO2007026218A2 (en) | 2005-09-01 | 2007-03-08 | Pfizer Japan Inc. | Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists |
| WO2007031860A1 (en) | 2005-09-15 | 2007-03-22 | Pfizer Japan Inc. | Indane substituted benzimidazoles and their use as acid pump inhibitors |
| WO2007072142A2 (en) | 2005-12-19 | 2007-06-28 | Pfizer Japan Inc. | Benzimidazole-5-carboxamide derivatives |
| BR122020004679B1 (pt) | 2005-12-19 | 2021-09-21 | Raqualia Pharma Inc | Composição farmacêutica |
| KR20080108129A (ko) | 2006-03-17 | 2008-12-11 | 라퀄리아 파마 인코포레이티드 | 크로메인 유도체 |
| EP2004631A1 (en) | 2006-04-12 | 2008-12-24 | Merck Patent GmbH | N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases |
| FR2901472B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants |
| FR2901473B1 (fr) | 2006-05-24 | 2010-08-13 | Oreal | Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide |
| WO2008035195A1 (en) | 2006-09-21 | 2008-03-27 | Raqualia Pharma Inc. | Benzimidazole derivatives as selective acid pump inhibitors |
| WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| WO2008059373A1 (en) | 2006-11-17 | 2008-05-22 | Raqualia Pharma Inc. | Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| WO2008114123A1 (en) | 2007-03-21 | 2008-09-25 | Raqualia Pharma Inc. | Spiro benzimidazole derivatives as acid pump inhibitors |
| WO2008124524A2 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Aryl sulfonamide compounds as modulators of the cck2 receptor |
| WO2008124518A1 (en) | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| JP5492770B2 (ja) | 2007-06-26 | 2014-05-14 | サノフイ | ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成 |
| RU2379043C2 (ru) | 2007-08-02 | 2010-01-20 | Закрытое акционерное общество "Биологические исследования и системы" | Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы |
| WO2009020768A1 (en) | 2007-08-07 | 2009-02-12 | President And Fellows Of Harvard College | Targeting the oncoprotein nucleophosmin |
| TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| BRPI1009145A2 (pt) | 2009-03-31 | 2016-04-19 | Zeria Pharm Co Ltd | método para a fabricação de derivado de benzodiazepina |
| MX2012000275A (es) | 2009-07-09 | 2012-02-08 | Raqualia Pharma Inc | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. |
| CA2775204A1 (en) | 2009-09-24 | 2011-03-31 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors |
| RU2017109664A (ru) | 2009-10-06 | 2019-01-23 | Милленниум Фармасьютикалз, Инк. | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 |
| AU2010319298B2 (en) | 2009-11-13 | 2015-11-05 | Plastipak Packaging, Inc. | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions |
| WO2011063164A2 (en) | 2009-11-18 | 2011-05-26 | Steady Sleep Rx Co., Inc. | Sustained release cannabinoid medicaments |
| WO2011133722A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
| US9000054B2 (en) | 2010-08-12 | 2015-04-07 | Senomyx, Inc. | Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer |
| US20120231083A1 (en) | 2010-11-18 | 2012-09-13 | The Board Of Trustees Of The University Of Illinois | Sustained release cannabinoid medicaments |
| EP2640379A4 (en) | 2010-11-18 | 2014-08-13 | Pier Pharmaceuticals | LOW DOSED CANNABINOIDARY MEDICINES |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| RU2634708C9 (ru) | 2011-11-07 | 2018-05-11 | Массачусетс Инститьют Оф Текнолоджи | Оксоалкилиденовые комплексы вольфрама для z-селективного метатезиса олефинов |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
-
2014
- 2014-11-21 MX MX2016006657A patent/MX2016006657A/es unknown
- 2014-11-21 ES ES14815149T patent/ES2870538T3/es active Active
- 2014-11-21 CA CA2929858A patent/CA2929858C/en active Active
- 2014-11-21 BR BR112016011727A patent/BR112016011727A2/pt not_active Application Discontinuation
- 2014-11-21 AU AU2014352875A patent/AU2014352875B2/en active Active
- 2014-11-21 PL PL14815149T patent/PL3071206T3/pl unknown
- 2014-11-21 RU RU2016124538A patent/RU2693484C1/ru active
- 2014-11-21 CN CN201480073822.0A patent/CN106163527A/zh active Pending
- 2014-11-21 US US14/550,233 patent/US10709714B2/en active Active
- 2014-11-21 KR KR1020167015759A patent/KR102254957B1/ko active Active
- 2014-11-21 JP JP2016533607A patent/JP6502939B2/ja active Active
- 2014-11-21 DK DK14815149.1T patent/DK3071206T3/da active
- 2014-11-21 EP EP14815149.1A patent/EP3071206B1/en active Active
- 2014-11-21 WO PCT/US2014/066832 patent/WO2015077572A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016011727A2 (pt) | 2017-08-08 |
| JP2016538295A (ja) | 2016-12-08 |
| WO2015077572A1 (en) | 2015-05-28 |
| RU2016124538A (ru) | 2017-12-27 |
| AU2014352875A1 (en) | 2016-05-26 |
| PL3071206T3 (pl) | 2022-01-17 |
| AU2014352875B2 (en) | 2019-10-24 |
| CN106163527A (zh) | 2016-11-23 |
| US20150148339A1 (en) | 2015-05-28 |
| EP3071206A1 (en) | 2016-09-28 |
| EP3071206B1 (en) | 2021-02-17 |
| ES2870538T3 (es) | 2021-10-27 |
| KR102254957B1 (ko) | 2021-05-25 |
| DK3071206T3 (da) | 2021-05-25 |
| RU2693484C1 (ru) | 2019-07-03 |
| CA2929858A1 (en) | 2015-05-28 |
| MX2016006657A (es) | 2016-10-12 |
| CA2929858C (en) | 2022-03-29 |
| AU2014352875A8 (en) | 2016-06-30 |
| US10709714B2 (en) | 2020-07-14 |
| KR20160088891A (ko) | 2016-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tabatabaei-Malazy et al. | New horizons in treatment of osteoporosis | |
| Folli et al. | Bariatric surgery and bone disease: from clinical perspective to molecular insights | |
| Argilés et al. | Novel approaches to the treatment of cachexia | |
| Thomas | Intermittent parathyroid hormone therapy to increase bone formation | |
| Figliomeni et al. | One year in review 2018: progress in osteoporosis treatment | |
| Israeli et al. | Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy | |
| JP6502939B2 (ja) | 骨粗鬆症の処置及び予防のためのガストリン拮抗薬 | |
| Xu et al. | Effects of different dosages of parathyroid hormone-related protein 1–34 on the bone metabolism of the ovariectomized rat model of osteoporosis | |
| Zheng et al. | Inhibition of substance P signaling aggravates the bone loss in ovariectomy-induced osteoporosis | |
| ESHRE Capri Workshop Group | Bone fractures after menopause | |
| Watanabe et al. | Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy | |
| Zhou et al. | Electroacupuncture ameliorates subchondral bone deterioration and inhibits cartilage degeneration in ovariectomised rats | |
| Abo-Elenin et al. | An overview of osteoporosis and possible treatment approaches | |
| Gowen et al. | Emerging therapies for osteoporosis | |
| Stathopoulos et al. | A review on osteoporosis in men | |
| Igarashi et al. | Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats | |
| Appelman-Dijkstra et al. | Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches | |
| Vashghani Farahani et al. | The effects of pentoxifylline adminstration on fracture healing in a postmenopausal osteoporotic rat model | |
| Mohanty et al. | Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review | |
| HK1230487A1 (en) | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis | |
| Fasipe et al. | Osteoporosis Now and in the Future: The Role of Newer Emerging Agents in the Management of Osteoporotic Bone Diseases–A Review | |
| Ara et al. | Journal Homepage:-www. journalijar. com | |
| Bao et al. | Lithium chloride enhances osteoblast differentiation and resists senile osteoporosis | |
| Abo-Rayah et al. | Forskolin Could Protect Against Flutamide-Induced Osteoporosis By Modulation of Serum Osteocalcin and Sclerostin In Rats | |
| Zhu | Targeting TGFβ1 Signaling: A Sustained-release, Monthly Intra-articular Injection Intervention for Early Osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161007 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171116 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181030 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190322 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6502939 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |